Charles River Laboratories International (CRL) EBT (2009 - 2026)

Charles River Laboratories International's EBT history runs 17 years deep, the most recent figure standing at -$294.1 million for Q4 2025.

• In Q4 2025, EBT fell 35.66% year-over-year to -$294.1 million; the TTM figure through Dec 2025 stood at -$99.5 million (down 206.86% YoY), while the FY2025 annual figure was -$99.5 million, down 206.86% from the prior year.
• EBT for Q4 2025 stood at -$294.1 million, down from $87.2 million in the prior quarter.
• The five-year high for EBT was $244.9 million in Q4 2022, with the low at -$294.1 million in Q4 2025.
• The 5-year median for EBT is $116.3 million (2023), against an average of $83.9 million.
• The sharpest annual moves came in 2022 and 2024: EBT surged 67.18% in 2022, then tumbled 203.87% in 2024.
• Charles River Laboratories International's EBT stood at $163.6 million in 2021, then soared by 49.67% to $244.9 million in 2022, then dropped by 14.79% to $208.7 million in 2023, then sank by 203.87% to -$216.8 million in 2024, then slumped by 35.66% to -$294.1 million in 2025.
• Business Quant data shows CRL's EBT at -$294.1 million in Q4 2025, $87.2 million in Q3 2025, and $71.4 million in Q2 2025.